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Background
FBP (aka Folate Receptor-a) is an immunogenic protein
that is over-expressed in breast, endometrial (EC) and
ovarian cancer (OC). FBP expression in malignant cells
is 20-80 fold higher compared to the limited distribution
in normal cells. We have completed enrollment of a
Phase IIa clinical trial with E39, an HLA-A2 restricted,
FBP peptide vaccine + GM-CSF. The vaccine is adminis-
tered in the adjuvant setting to prevent recurrences in
high-risk, EC and OC patients (pts) rendered clinically
disease-free with standard-of-care therapy. Here, we
summarize preliminary toxicity (tox), immunologic and
clinical response to vaccination.
Methods
HLA-A2+ pts are enrolled into the vaccine group (VG)
while HLA-A2- pts are being followed prospectively as
an untreated control group (CG). Six monthly intrader-
mal inoculations (V1-V6) of either100mcg, 500mcg, or
1000mcg of E39 + 250 mcg GM-CSF are administered
during the primary vaccine series (PVS). In vivo immu-
nologic responses are assessed by both local reactions
(LR) after each inoculation and delayed hypersensitivity
(DTH) reactions measured at baseline (R0) and after the
PVS (R6). Recurrences are determined clinically. Data
are means compared with a paired, t-test or Chi-square/
Fisher Exact test as appropriate.
Results
47 pts have enrolled; 25 in the VG and 22 in the CG.
There are no significant differences in age, grade, stage,
or nodal status between groups (all P > 0.20). Overall,
the vaccine was well-tolerated (max local tox: 96%
Grade (Gr) 1, 4% Gr 2; max systemic tox: 56.5% Gr 1,
26.1% Gr 2, 4.3% Gr 3). The LR significantly increased
from V1 to V2 (45.6mm ± 5.5 v 71.9mm ± 6.6, p <
0.01), and then plateaued between V3 and V6 (93.4mm
± 8.3 v 102.4mm ± 10.6, p = 0.51). With 14 patients
having completed the PVS, DTH trended toward an
increase from R0 to R6 (7.15mm ± 1.7 v 15.8mm ± 4.2,
p = 0.07). After a median follow-up of 13 months, there
have been 11/22 (50%) recurrences in the CG compared
to 8/25 (32%) recurrences in the VG (p = 0.25).
Conclusions
Current results from this Phase IIa trial indicate the E39
vaccine is well-tolerated and elicits a strong in vivo immune
response. Preliminarily, the vaccine appears to reduce the
risk of recurrence in adjuvant treated EC and OC patients.
In contrast to other FBP-directed cytotoxic agents, the E39
vaccine holds the promise of a sustained immunologic
response and memory against FBP-expressing recurrences
with minimal toxicity.
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